News
-
![]()
Press Releases
-
![Informative content aimed at educating the public about lung cancer, early detection methods, the importance of biomarkers, and general health tips related to cancer prevention and care.]()
Educational Articles
-
![Detailed scientific studies and findings related to lung cancer detection, biomarker research, and other relevant medical research conducted or published by Cizzle Bio or related entities.]()
Research Papers
Cizzle Bio News
Stay informed with the latest updates on Cizzle Bio's milestones, industry news, and significant events. Here, you will find:
-
![Business professionals reviewing company milestones and progress reports in lung cancer diagnostics, highlighting key achievements in medical innovation.]()
Company Milestones
Discover our key achievements and progress in developing cutting-edge lung cancer diagnostics.
-
![Digital collage of news screens showcasing the latest trends and advancements in the biotechnology field, highlighting industry news and updates.]()
Industry News
Keep up with the latest trends and advancements in the biotechnology field.
-
![Doctor and business professional shaking hands, symbolizing strategic partnerships and collaborations to enhance cancer detection efforts.]()
Collaborations and Partnerships
Learn about our strategic partnerships and collaborative efforts to enhance cancer detection.
-
![Doctor presenting at a conference, discussing significant events and advancements in healthcare and biotechnology, highlighting Cizzle Bio's impact.]()
Significant Events
Get insights into important events and conferences that highlight our impact on healthcare and biotechnology.
Latest
Cizzle Bio, Inc. Partners with Moffitt Cancer Center to Advance Lung Cancer Detection
Cizzle Bio, Inc. is proud to collaborate with Moffitt Cancer Center to clinically evaluate the CIZ1B biomarker test for early-stage lung cancer detection. This partnership represents a significant step in advancing lung cancer diagnostics and improving patient care.
Revolutionizing Lung Cancer Detection: Cizzle Bio, Inc.'s New Partnership
Cizzle Bio, Inc. announces a groundbreaking partnership with Cizzle Biotechnology Holdings PLC, ushering in a new era of lung cancer detection technology in North America. Learn about how the advanced CIZ1B biomarker is set to change the landscape of healthcare.
ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection
ProteoGenix and Cizzle Biotechnology have developed new antibodies for early lung cancer detection. Explore the advancements and future impacts of this innovative partnership.
Strategic Licensing and Partnership: Cizzle Bio Inc.
Discover how Cizzle Biotechnology's new partnership aims to revolutionize lung cancer detection in North America through the CIZ1B biomarker test. Learn more about the strategic licensing agreement and its benefits.
Cizzle Bio, Inc. is proud to collaborate with Moffitt Cancer Center to clinically evaluate the CIZ1B biomarker test for early-stage lung cancer detection. This partnership represents a significant step in advancing lung cancer diagnostics and improving patient care.